provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission’s Public Reference Room, 100 F Street NE, Washington, DC 20549 on official business days between the hours of 10:00 a.m. and 3:00 p.m. Copies of such filing also will be available for inspection and copying at the principal office of the Exchange. All comments received will be posted without change. Persons submitting comments are cautioned that we do not redact or edit personal identifying information from comment submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR–ISE–2018–55, and should be submitted on or before July 16, 2018.

For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.49

Eduardo A. Aleman,
Assistant Secretary.

[FR Doc. 2018–13505 Filed 6–22–18; 8:45 am]
BILLING CODE 8011–01–P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–83463]
Draft 2018–2022 Strategic Plan for Securities and Exchange Commission

AGENCY: Securities and Exchange Commission.

ACTION: Request for comment.

SUMMARY: The Securities and Exchange Commission (SEC) is providing notice that it is seeking comments on its draft 2018–2022 Strategic Plan. The draft Strategic Plan includes a draft of the SEC’s mission, vision, values, strategic goals, and planned initiatives.

DATES: Comments should be received on or before July 25, 2018.

ADDRESSES: Comments may be submitted by any of the following methods:

Electronic Comments
Send an email to PerformancePlanning@sec.gov.

Paper Comments
Send paper comments to Nicole Puccio, Branch Chief, Office of Financial Management, at (202) 551–6638, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549–2521.50


By the Commission.

Dated: June 19, 2018.

Brent J. Fields,
Secretary.

[FR Doc. 2018–13484 Filed 6–22–18; 8:45 am]
BILLING CODE 8011–01–P

SECTORS AND EXCHANGE COMMISSION


Self-Regulatory Organizations; Cboe BZX Exchange, Inc.; Order Instituting Proceedings To Determine Whether To Approve or Disapprove a Proposed Rule Change, as Modified by Amendment No. 2 Thereto, To List and Trade Shares of Eighteen ADRPLUS Funds of the Precidian ETFs Trust Under Rule 14.11(i), Managed Fund Shares

June 19, 2018.

I. Introduction

On March 5, 2018, Cboe BZX Exchange, Inc. filed with the Securities and Exchange Commission (“Commission”), pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”)1 and Rule 19b–4 thereunder,2 a proposed rule change to list and trade shares (“Shares”) of eighteen ADRPLUS Funds (“Funds”) of the Precidian ETFs Trust (“Trust”). The proposed rule change was published for comment in the Federal Register on March 21, 2018.3 On April 25, 2018, the Exchange filed Amendment No. 1 to the proposed rule change,4 and the Commission, pursuant to Section 19(b)(2) of the Act,5 designated a longer

4 Amendment No. 1 replaced and superseded the original rule filing in its entirety. Amendment No. 1 is available at https://www.sec.gov/comments/sr-cboebzx-2018-019/cboebzx2018019-3551361-162325.pdf. Amendment No. 1 was subsequently replaced and superseded in its entirety by Amendment No. 2. See note 7, infra.

For purpose only of waiving the operative delay, the Commission has considered the proposed rule’s impact on efficiency, competition, and capital formation. See 15 U.S.C. 78c(f).

47 For purpose only of waiving the operative delay, the Commission has considered the proposed rule’s impact on efficiency, competition, and capital formation. See 15 U.S.C. 78c(f).
Specifically, the Exchange proposes to list Shares of Anheuser-Busch InBev SA/NV ADRPLUS Fund, AstraZeneca PLC ADRPLUS Fund, Banco Santander, S.A. ADRPLUS Fund, BP P.L.C. ADRPLUS Fund, British American Tobacco PLC ADRPLUS Fund, Diageo plc ADRPLUS Fund, GlaxoSmithKline plc ADRPLUS Fund, HSBC Holdings Plc ADRPLUS Fund, Mitsubishi UFJ Financial Group, Inc. ADRPLUS Fund, Novartis AG ADRPLUS Fund, Nova Nordisk A/S (B Shares) ADRPLUS Fund, Royal Dutch Shell plc (Class A) ADRPLUS Fund, Royal Dutch Shell plc (Class B) ADRPLUS Fund, Sanofi ADRPLUS Fund, SAP AG ADRPLUS Fund, Toyota Motor Corporation ADRPLUS Fund, and Vodafone Group Plc ADRPLUS Fund. The Funds are a series of, and the Shares will be offered by, the Trust, which was organized as a Delaware statutory trust on August 27, 2010. Precidian Funds LLC ("Advisor") will serve as the investment adviser to the Funds. The Exchange has made the following representations and statements in describing the Funds and their investment strategies.

A. Exchange’s Description of the ADRPLUS Funds

Each Fund seeks to provide investment results that correspond generally, before and after fees and expenses, to the price and yield performance of a particular American Depositary Receipt, hedged against fluctuations in the exchange rate between the U.S. dollar and the local currency of the foreign security underlying the American Depositary Receipt ("Local Currency"). The following chart lists the underlying company and the Local Currency for each of the Funds.

<table>
<thead>
<tr>
<th>Fund name</th>
<th>Underlying company</th>
<th>Local currency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anheuser-Busch InBev SA/NV ADRPLUS Fund</td>
<td>AstraZeneca PLC</td>
<td>Euro</td>
</tr>
<tr>
<td>AstraZeneca PLC ADRPLUS Fund</td>
<td>Banco Santander, S.A.</td>
<td>Euro</td>
</tr>
<tr>
<td>Diageo plc ADRPLUS Fund</td>
<td>GlaxoSmithKline plc</td>
<td>British pound.</td>
</tr>
<tr>
<td>GlaxoSmithKline plc ADRPLUS Fund</td>
<td>HSBC Holdings Plc</td>
<td>British pound.</td>
</tr>
<tr>
<td>Mitsubishi UFJ Financial Group, Inc. ADRPLUS Fund</td>
<td>Novartis AG</td>
<td>Swiss franc.</td>
</tr>
<tr>
<td>Novo Nordisk A/S (B Shares) ADRPLUS Fund</td>
<td>Royal Dutch Shell plc (Class A)</td>
<td>Danish kronen.</td>
</tr>
<tr>
<td>Royal Dutch Shell plc (Class B) ADRPLUS Fund</td>
<td>Sanofi ADRPLUS Fund</td>
<td>Euro</td>
</tr>
<tr>
<td>SAP AG ADRPLUS Fund</td>
<td></td>
<td>Euro</td>
</tr>
</tbody>
</table>

The Exchange proposes to list Shares of Anheuser-Busch InBev SA/NV ADRPLUS Fund, AstraZeneca PLC ADRPLUS Fund, Banco Santander, S.A. ADRPLUS Fund, BP P.L.C. ADRPLUS Fund, British American Tobacco plc ADRPLUS Fund, Diageo plc ADRPLUS Fund, GlaxoSmithKline plc ADRPLUS Fund, HSBC Holdings Plc ADRPLUS Fund, Mitsubishi UFJ Financial Group, Inc. ADRPLUS Fund, Novartis AG ADRPLUS Fund, Nova Nordisk A/S (B Shares) ADRPLUS Fund, Royal Dutch Shell plc (Class A) ADRPLUS Fund, Royal Dutch Shell plc (Class B) ADRPLUS Fund, Sanofi ADRPLUS Fund, SAP AG ADRPLUS Fund, Toyota Motor Corporation ADRPLUS Fund, and Vodafone Group Plc ADRPLUS Fund. The Funds are a series of, and the Shares will be offered by, the Trust, which was organized as a Delaware statutory trust on August 27, 2010. Precidian Funds LLC ("Advisor") will serve as the investment adviser to the Funds. The Exchange has made the following representations and statements in describing the Funds and their investment strategies.

Specifically, the Exchange proposes to list Shares of Anheuser-Busch InBev SA/NV ADRPLUS Fund, AstraZeneca PLC ADRPLUS Fund, Banco Santander, S.A. ADRPLUS Fund, BP P.L.C. ADRPLUS Fund, British American Tobacco plc ADRPLUS Fund, Diageo plc ADRPLUS Fund, GlaxoSmithKline plc ADRPLUS Fund, HSBC Holdings Plc ADRPLUS Fund, Mitsubishi UFJ Financial Group, Inc. ADRPLUS Fund, Novartis AG ADRPLUS Fund, Nova Nordisk A/S (B Shares) ADRPLUS Fund, Royal Dutch Shell plc (Class A) ADRPLUS Fund, Royal Dutch Shell plc (Class B) ADRPLUS Fund, Sanofi ADRPLUS Fund, SAP AG ADRPLUS Fund, Toyota Motor Corporation ADRPLUS Fund, and Vodafone Group Plc ADRPLUS Fund. The Funds are a series of, and the Shares will be offered by, the Trust, which was organized as a Delaware statutory trust on August 27, 2010. Precidian Funds LLC ("Advisor") will serve as the investment adviser to the Funds. The Exchange has made the following representations and statements in describing the Funds and their investment strategies.

A. Exchange’s Description of the ADRPLUS Funds

Each Fund seeks to provide investment results that correspond generally, before and after fees and expenses, to the price and yield performance of a particular American Depositary Receipt, hedged against fluctuations in the exchange rate between the U.S. dollar and the local currency of the foreign security underlying the American Depositary Receipt ("Local Currency"). The following chart lists the underlying company and the Local Currency for each of the Funds.

<table>
<thead>
<tr>
<th>Fund name</th>
<th>Underlying company</th>
<th>Local currency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anheuser-Busch InBev SA/NV ADRPLUS Fund</td>
<td>AstraZeneca PLC</td>
<td>Euro</td>
</tr>
<tr>
<td>AstraZeneca PLC ADRPLUS Fund</td>
<td>Banco Santander, S.A.</td>
<td>Euro</td>
</tr>
<tr>
<td>Diageo plc ADRPLUS Fund</td>
<td>GlaxoSmithKline plc</td>
<td>British pound.</td>
</tr>
<tr>
<td>GlaxoSmithKline plc ADRPLUS Fund</td>
<td>HSBC Holdings Plc</td>
<td>British pound.</td>
</tr>
<tr>
<td>Mitsubishi UFJ Financial Group, Inc. ADRPLUS Fund</td>
<td>Novartis AG</td>
<td>Swiss franc.</td>
</tr>
<tr>
<td>Novo Nordisk A/S (B Shares) ADRPLUS Fund</td>
<td>Royal Dutch Shell plc (Class A)</td>
<td>Danish kronen.</td>
</tr>
<tr>
<td>Royal Dutch Shell plc (Class B) ADRPLUS Fund</td>
<td>Sanofi ADRPLUS Fund</td>
<td>Euro</td>
</tr>
<tr>
<td>SAP AG ADRPLUS Fund</td>
<td></td>
<td>Euro</td>
</tr>
</tbody>
</table>

The Exchange proposes to list Shares of Anheuser-Busch InBev SA/NV ADRPLUS Fund, AstraZeneca PLC ADRPLUS Fund, Banco Santander, S.A. ADRPLUS Fund, BP P.L.C. ADRPLUS Fund, British American Tobacco plc ADRPLUS Fund, Diageo plc ADRPLUS Fund, GlaxoSmithKline plc ADRPLUS Fund, HSBC Holdings Plc ADRPLUS Fund, Mitsubishi UFJ Financial Group, Inc. ADRPLUS Fund, Novartis AG ADRPLUS Fund, Nova Nordisk A/S (B Shares) ADRPLUS Fund, Royal Dutch Shell plc (Class A) ADRPLUS Fund, Royal Dutch Shell plc (Class B) ADRPLUS Fund, Sanofi ADRPLUS Fund, SAP AG ADRPLUS Fund, Toyota Motor Corporation ADRPLUS Fund, and Vodafone Group Plc ADRPLUS Fund. The Funds are a series of, and the Shares will be offered by, the Trust, which was organized as a Delaware statutory trust on August 27, 2010. Precidian Funds LLC ("Advisor") will serve as the investment adviser to the Funds. The Exchange has made the following representations and statements in describing the Funds and their investment strategies.

Specifically, the Exchange proposes to list Shares of Anheuser-Busch InBev SA/NV ADRPLUS Fund, AstraZeneca PLC ADRPLUS Fund, Banco Santander, S.A. ADRPLUS Fund, BP P.L.C. ADRPLUS Fund, British American Tobacco plc ADRPLUS Fund, Diageo plc ADRPLUS Fund, GlaxoSmithKline plc ADRPLUS Fund, HSBC Holdings Plc ADRPLUS Fund, Mitsubishi UFJ Financial Group, Inc. ADRPLUS Fund, Novartis AG ADRPLUS Fund, Nova Nordisk A/S (B Shares) ADRPLUS Fund, Royal Dutch Shell plc (Class A) ADRPLUS Fund, Royal Dutch Shell plc (Class B) ADRPLUS Fund, Sanofi ADRPLUS Fund, SAP AG ADRPLUS Fund, Toyota Motor Corporation ADRPLUS Fund, and Vodafone Group Plc ADRPLUS Fund. The Funds are a series of, and the Shares will be offered by, the Trust, which was organized as a Delaware statutory trust on August 27, 2010. Precidian Funds LLC ("Advisor") will serve as the investment adviser to the Funds. The Exchange has made the following representations and statements in describing the Funds and their investment strategies.

A. Exchange’s Description of the ADRPLUS Funds

Each Fund seeks to provide investment results that correspond generally, before and after fees and expenses, to the price and yield performance of a particular American Depositary Receipt, hedged against fluctuations in the exchange rate between the U.S. dollar and the local currency of the foreign security underlying the American Depositary Receipt ("Local Currency"). The following chart lists the underlying company and the Local Currency for each of the Funds.

<table>
<thead>
<tr>
<th>Fund name</th>
<th>Underlying company</th>
<th>Local currency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anheuser-Busch InBev SA/NV ADRPLUS Fund</td>
<td>AstraZeneca PLC</td>
<td>Euro</td>
</tr>
<tr>
<td>AstraZeneca PLC ADRPLUS Fund</td>
<td>Banco Santander, S.A.</td>
<td>Euro</td>
</tr>
<tr>
<td>Diageo plc ADRPLUS Fund</td>
<td>GlaxoSmithKline plc</td>
<td>British pound.</td>
</tr>
<tr>
<td>GlaxoSmithKline plc ADRPLUS Fund</td>
<td>HSBC Holdings Plc</td>
<td>British pound.</td>
</tr>
<tr>
<td>Mitsubishi UFJ Financial Group, Inc. ADRPLUS Fund</td>
<td>Novartis AG</td>
<td>Swiss franc.</td>
</tr>
<tr>
<td>Novo Nordisk A/S (B Shares) ADRPLUS Fund</td>
<td>Royal Dutch Shell plc (Class A)</td>
<td>Danish kronen.</td>
</tr>
<tr>
<td>Royal Dutch Shell plc (Class B) ADRPLUS Fund</td>
<td>Sanofi ADRPLUS Fund</td>
<td>Euro</td>
</tr>
<tr>
<td>SAP AG ADRPLUS Fund</td>
<td></td>
<td>Euro</td>
</tr>
</tbody>
</table>
Each of the Funds will hold only: (i) Shares of an American Depositary Receipt ("Unhedged ADR") listed on a U.S. national securities exchange; (ii) OTC currency swaps that hedge against fluctuations in the exchange rate ("Exchange Rate") between the U.S. dollar and the Local Currency ("Currency Hedge"); and (iii) cash and cash equivalents.\(^{(13)}\)

The Exchange states that the Funds will provide investors with the opportunity to easily eliminate currency exposure that they may not even realize exists with Unhedged ADRs without having to transact in the currency derivatives market. The Exchange believes that this confers a significant benefit to investors and the broader marketplace by adding transparency and simplifying the process of eliminating risk from an investor’s portfolio. As further described below in the section entitled Policy Discussion, the Exchange believes that the policy concerns underlying the listing rules which the Funds would or may not meet, specifically Rules 14.11(i)(4)(C)(i)(3)–(4)\(^{(14)}\) and 14.11(i)(4)(C)(v),\(^{(15)}\) are mitigated by the structure, holdings, and purpose of the Funds.

\(^{(13)}\)The Exchange states that for purposes of this filing and consistent with Rule 14.11(i)(4)(C)(iii), cash equivalents are short-term instruments with maturities of less than three months, that include only the following Government securities, including bills, notes, and bonds differing as to maturity and rates of interest, which are either issued or guaranteed by the U.S. Treasury or by U.S. Government agencies or instrumentalities; (ii) certificates of deposit issued against funds deposited in a bank or savings and loan association; (iii) bankers acceptances, which are short-term credit instruments used to finance commercial transactions; (iv) repurchase agreements and reverse repurchase agreements; (v) bank time deposits, which are monies kept on deposit with banks or savings and loan associations for a stated period of time at a fixed rate of interest; (vi) commercial paper, which are short-term unsecured promissory notes; and (vii) money market funds.

\(^{(14)}\)The Exchange states that the Funds will not meet: (i) the requirement under Exchange Rule 14.11(i)(4)(C)(i)(3) that the most heavily weighted component stock shall not exceed 30% of the equity weight of the portfolio; and (ii) the requirement under Exchange Rule 14.11(i)(4)(C)(i)(4) that the equity portion of the portfolio shall include a minimum of 13 component stocks.

\(^{(15)}\)The Exchange states that the Funds may not meet the requirement under Exchange Rule 14.11(i)(4)(C)(v) that the aggregate gross notional value of OTC derivatives shall not exceed 20% of the weight of the portfolio (including gross notional exposures).

The Trust is required to comply with Rule 10A–3 under the Act\(^{(16)}\) for the initial and continued listing of the Shares of each Fund. In addition, the Exchange represents that the Shares of each Fund will meet and be subject to all other requirements of the Generic Listing Rules, as defined below, and other applicable continued listing requirements for Managed Fund Shares under Exchange Rule 14.11(i), including those requirements regarding the Disclosed Portfolio (as defined in the Exchange rules) and the requirement that the Disclosed Portfolio and the NAV will be made available to all market participants at the same time,\(^{(17)}\) intraday indicative value,\(^{(18)}\) suspension of trading or removal,\(^{(19)}\) trading halts,\(^{(20)}\) disclosure,\(^{(21)}\) firwalls,\(^{(22)}\) and surveillance.\(^{(23)}\) Further, at least 100,000 Shares of each Fund will be outstanding upon the commencement of trading.\(^{(24)}\) The Exchange also provides that all statements and representations made in the filing regarding the description of the portfolio or reference assets, limitations on portfolio holdings or reference assets, dissemination and availability of reference assets and intraday indicative values, and the applicability of Exchange listing rules specified in the filing will constitute continued listing requirements for the Funds. The Exchange states that the Trust, on behalf of the Funds, has represented to the Exchange that it will advise the Exchange of any failure by a Fund or the Shares to comply with the continued listing requirements, and, pursuant to its obligations under Section 19(g)(1) of the Act, the Exchange will surveil for compliance with the continued listing requirements. If a Fund or the Shares are not in compliance with the applicable listing requirements, the Exchange will commence delisting procedures under Exchange Rule 14.12.

B. Exchange’s Policy Discussion

The Exchange believes that, while the Funds do not meet the Generic Listing Standards, in particular Rules 14.11(i)(4)(C)(i)(3) and (4) and 14.11(i)(4)(C)(v), the policy issues that those rules are intended to address are otherwise mitigated by the structure, holdings, and purpose of the Funds.\(^{(25)}\) The Exchange believes that Rule 14.11(i)(4)(C)(i)(a)(3) is intended to ensure that no single equity security constitutes too concentrated of a position in a series of Managed Fund Shares, and Rule 14.11(i)(4)(C)(i)(a)(4) is similarly intended to diversify the holdings of a series of Managed Fund Shares. The Exchange believes that these policy concerns are mitigated because: (i) The Unhedged ADR will meet the market cap and liquidity requirements of Rules 14.11(i)(4)(C)(i)(a)(1) and (2); and (ii) the intended function of the Funds is to eliminate currency exposure risk for a single security, which means that the Funds are necessarily concentrated. The Exchange represents that the creation and redemption mechanism will provide a near frictionless arbitrage opportunity that would minimize the risk of manipulation of either the Unhedged ADR or the applicable Fund and, thus, mitigate the manipulation concerns that Rule 14.11(i)(4)(C)(i)(a)(3) and (4) were intended to address.

The Exchange also believes that the policy issues that Rule 14.11(i)(4)(C)(v) is intended to address are also mitigated by the way that the Funds would use OTC currency swaps. According to the Exchange, the rule is intended to mitigate concerns around the manipulability of a particular underlying reference asset or derivatives contract and to minimize counterparty risk. While the Currency Hedge positions taken by the Currency Hedged ADRs would not meet the Generic Listing Standards related to OTC

\(^{(16)}\)17 CFR 240.10A–3.


\(^{(20)}\)See Exchange Rule 14.11(i)(4)(B)(iv). The Exchange also believes that the Unhedged ADR will meet the market cap and liquidity requirements of Rules 14.11(i)(4)(C)(i)(a)(1) and (2); and (ii) the intended function of the Funds is to eliminate currency exposure risk for a single security, which means that the Funds are necessarily concentrated. The Exchange represents that the creation and redemption mechanism will provide a near frictionless arbitrage opportunity that would minimize the risk of manipulation of either the Unhedged ADR or the applicable Fund and, thus, mitigate the manipulation concerns that Rule 14.11(i)(4)(C)(i)(a)(3) and (4) were intended to address.

The Exchange also believes that the policy issues that Rule 14.11(i)(4)(C)(v) is intended to address are also mitigated by the way that the Funds would use OTC currency swaps. According to the Exchange, the rule is intended to mitigate concerns around the manipulability of a particular underlying reference asset or derivatives contract and to minimize counterparty risk. While the Currency Hedge positions taken by the Currency Hedged ADRs would not meet the Generic Listing Standards related to OTC

\(^{(25)}\)25 The Exchange represents that each Fund expects to invest in excess of 95% of its net assets in the Unhedged ADRs, and each Fund expects that the gross notional value of the Currency Hedge would be equal to the value of the Unhedged ADRs, which would be approximately 50% of the weight of the portfolio (including gross notional exposures).
derivatives holdings, the Exchange believes that the policy concerns about limiting exposure to potentially manipulative underlying reference assets that the Generic Listing Standards are intended to address are otherwise mitigated by the liquidity in the underlying spot currency market that prevents manipulation of the reference prices used by the Currency Hedge. Further, the Exchange states that the Funds will attempt to limit counterparty risk in OTC currency swaps by: (i) Entering into such contracts only with counterparties the Advisor believes are creditworthy; (ii) limiting a Fund’s exposure to each counterparty; and (iii) monitoring the creditworthiness of each counterparty and the Fund’s exposure to each counterparty on an ongoing basis. The Exchange believes that counterparty risk associated with OTC currency swaps is further mitigated because the currency swaps are settled on a daily basis and, thus, the counterparty risk for any particular swap is limited in two ways—first, that the counterparty credit exposure is always limited to a 24 hour period and second, that the exposure of the swap is only to the movement in the currencies over that same 24 hour period.

III. Proceedings To Determine Whether To Approve or Disapprove SR-CboeBZX–2018–019 and Grounds for Disapproval Under Consideration

The Commission is instituting proceedings pursuant to Section 19(b)(2)(B) of the Act to determine whether the proposed rule change, as modified by Amendment No. 2, should be approved or disapproved. Institution of such proceedings is appropriate at this time in view of the legal and policy issues raised by the proposed rule change. Institution of proceedings does not indicate that the Commission has reached any conclusions with respect to any of the issues involved. Rather, as described below, the Commission seeks and encourages interested persons to provide comments on the proposed rule change.

Pursuant to Section 19(b)(2)(B) of the Act, the Commission is providing notice of the grounds for disapproval under consideration. The Commission is instituting proceedings to allow for additional analysis of the proposed rule change’s consistency with Section 6(b)(5) of the Act, which requires, among other things, that the rules of a national securities exchange be “designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade,” and “to protect investors and the public interest.”

IV. Procedure: Request for Written Comments

The Commission requests that interested persons provide written submissions of their views, data, and arguments with respect to the issues identified above, as well as any other concerns they may have with the proposal. In particular, the Commission invites the written views of interested persons concerning whether the proposal is consistent with Section 6(b)(5) or any other provision of the Act, or the rules and regulations thereunder. Although there do not appear to be any issues relevant to approval or disapproval that would be facilitated by an oral presentation of views, data, and arguments, the Commission will consider, pursuant to Rule 19b–4, any request for an opportunity to make an oral presentation. Interested persons are invited to submit written data, views, and arguments regarding whether the proposal should be approved or disapproved by July 12, 2018. Any person who wishes to file a rebuttal to any other person’s submission must file that rebuttal by July 30, 2018. The Commission asks that commenters address the sufficiency of the Exchange’s statements in support of the proposal, which are set forth in Amendment No. 2 to the proposed rule change, in addition to any other comments they may wish to submit about the proposed rule change.

The Commission notes that the Exchange proposes to list and trade, pursuant to its Rule 14.11(i), Managed Fund Shares of Funds that would invest in shares of a single Unhedged ADR, along with a Currency Hedge and cash and cash equivalents. A proposal to list and trade Managed Fund Shares that are designed to reflect, generally, the price and performance of a single equity security, hedged against fluctuations in a given exchange rate, is novel. Accordingly, the Commission specifically seeks comment on whether it is appropriate to permit the listing and trading of shares of an exchange-traded fund with underlying holdings concentrated in a single (or a few) equity securities. What impact, if any, would such shares have on the market for the underlying equity security (or securities)? What impact, if any, would such shares have on the equity markets more generally, especially if funds investing in a single equity security proliferate? Are the listing and trading of such shares consistent with the requirements of Section 6(b)(5) of the Act, which, among other things, requires that the rules of an exchange be designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, and, in general, to protect investors and the public interest?

Comments may be submitted by any of the following methods:

Electronic Comments

• Use the Commission’s internet comment form (http://www.sec.gov/rules/sro.shtml);
• Send an email to rule-comments@sec.gov. Please include File Number SR-CboeBZX–2018–019 on the subject line.

Paper Comments

• Send paper comments in triplicate to Secretary, Securites and Exchange Commission, 100 F Street NE, Washington, DC 20549–1090. All submissions should refer to File Numbers SR-CboeBZX–2018–019. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission’s internet website (http://www.sec.gov/rules/sro.shtml). Copies of the submission, all subsequent amendments, all written statements or communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission’s Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10:00 a.m. and 3:00 p.m. Copies of these filings also will be available for inspection and copying at the principal office of the Exchange. All comments received will be posted without change; the Commission does not edit personal
SECURITIES AND EXCHANGE COMMISSION


Self-Regulatory Organizations: The Nasdaq Stock Market LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Relocate the Exchange’s Rules Pertaining to Co-Location and Direct Connectivity

June 19, 2018.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),1 and Rule 19b–4 thereunder,2 the Securities and Exchange Commission (the “Commission”) has received a self-regulatory organization’s (“SRO’s”) proposed rule change. The Exchange proposes to relocate its rules governing co-location and direct connectivity services, which presently comprise Rules 7034 and 7051, respectively. The Exchange proposes to establish, within its new rulebook shell,3 a new General 8 heading, entitled “Connectivity,” to renumber Rule 7034 as Section 1 thereunder, and to renumber Rule 7051 as Section 2 thereunder. The Exchange furthermore proposes to amend Equity Rules 7007, 7015, 7025, and 7030, and Options Rules, Chapter XV to update cross references therein to Rules 7034 and 7051.4 The Exchange also proposes to update internal cross-references in the renumbered Rules.

The Exchange considers it appropriate to relocate these Rules to better organize its Rulebook. The other Affiliated Exchanges intend to propose similar reorganizations of their co-location and direct connectivity rules so that these rules will be harmonized among all of the Affiliated Exchanges.

The relocation of the co-location and direct connectivity rules is part of the Exchange’s continued effort to promote efficiency and conformity of its processes with those of its Affiliated Exchanges. The Exchange believes that moving the co-location and direct connectivity rules to their new location will facilitate the use of the Rulebook by Members of the Exchange who are members of other Affiliated Exchanges. Moreover, the proposed changes are of a non-substantive nature and will not amend the relocated rules other than to update their numbers and make conforming cross-reference changes.

II. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

The Exchange proposes to relocate its rules governing co-location and direct connectivity services, which presently comprise Rules 7034 and 7051, respectively. The Exchange proposes to establish, within its new rulebook shell, a new General 8 heading, entitled “Connectivity,” to renumber Rule 7034 as Section 1 thereunder, and to renumber Rule 7051 as Section 2 thereunder. The Exchange furthermore proposes to amend Equity Rules 7007, 7015, 7025, and 7030, and Options Rules, Chapter XV to update cross references therein to Rules 7034 and 7051. The Exchange also proposes to update internal cross-references in the renumbered Rules.

The Exchange considers it appropriate to relocate these Rules to better organize its Rulebook. The other Affiliated Exchanges intend to propose similar reorganizations of their co-location and direct connectivity rules so that these rules will be harmonized among all of the Affiliated Exchanges.

The relocation of the co-location and direct connectivity rules is part of the Exchange’s continued effort to promote efficiency and conformity of its

1 Recently, the Exchange added a shell structure to its Rulebook with the purpose of improving efficiency and readability and to align its rules closer to those of its five sister exchanges: Nasdaq BX, Inc.; Nasdaq PHIX LLC; Nasdaq ISE, LLC; Nasdaq GEMX, LLC; and Nasdaq MRX, LLC (together with Nasdaq, the “Affiliated Exchanges”). See Securities Exchange Act Release No. 82175 (November 29, 2017), 82 FR 57494 (December 5, 2017) (SR–NASDAQ–2017–125).
2 In addition to the above, the Exchange proposes to delete language that exists presently in Rule 7034(b) (“Connectivity to Third Party Services”) and Rule 7051(b) (“Direct Circuit Connection To Third Party Services”) that each refer to expired waivers of fees for connections to third party services that were applicable “through April 30, 2017.”